A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Conditions
Systemic Lupus Erythematosus (With and Without Nephritis) · Idiopathic Inflammatory Myopathy · Systemic Sclerosis
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Mayo Clinic, Phoenix, Arizona, United States
Contact: Principal Investigator (Vivek Nagaraja, MD)Loma Linda University Medical Center, Loma Linda, California, United States
Contact: Principal Investigator (Hisham Abdel-Azim, MD)University of Colorado Denver, Aurora, Colorado, United States
Contact: Principal Investigator (Melissa Griffith, MD)Mayo Clinic, Jacksonville, Florida, United States
Contact: Principal Investigator (Vikas Majithia, MD)The University of Chicago Medical Center, Chicago, Illinois, United States
Contact: Principal Investigator (Michael Macklin, MD)University of Iowa, Iowa City, Iowa, United States
Contact: Principal Investigator (Hanna Zembrzuska, MD)Norton Cancer Institute, St. Matthews Campus, Louisville, Kentucky, United States
Contact: Principal Investigator (Don Stevens, MD)Astera Cancer Care, East Brunswick, New Jersey, United States
Contact: Principal Investigator (Birju Bhatt, MD)Icahn School of Medicine at Mount Sinai, New York, New York, United States
Contact: Principal Investigator (Margrit Wiesendanger, MD)Duke University Medical Center, Durham, North Carolina, United States
Contact: Principal Investigator (Lisa Criscione-Schreiber, MD)Medical University of South Carolina, Charleston, South Carolina, United States
Contact: Principal Investigator (Melissa Cunningham, MD)Prisma Health, Greenville, South Carolina, United States
Contact: Principal Investigator (Cory McGee, MD)LDS Hospital - lntermountain Health, Salt Lake City, Utah, United States
Contact: Principal Investigator (Pankhuri Gupta, MD)Hôpital Maisonneuve Rosemont, Montreal, Quebec, Canada
Contact: Principal Investigator (Nicolas Richard, MD)
Study leads
Allogene Study Director
Study Director
Allogene Therapeutics, Inc.